Oral Peptide Therapeutics: Dr. Kim Virtual Integrative and Functional Medicine San Antonio TX - serving IA, IL, MO, GA, FL, TX

John Kim
Dec 6, 2025
12 min read

Updated: Apr 28

A Comprehensive Review of Bioavailability, Molecular Mechanisms, and Clinical EvidenceYoon Hang Kim, MD www.yoonhangkim.com

Abstract

Oral peptide delivery represents one of the most significant pharmacological challenges in modern therapeutics. Despite the inherent instability of peptides in the gastrointestinal environment, several peptides have demonstrated remarkable oral bioavailability through various mechanisms including intrinsic stability, absorption enhancer co-formulation, and specialized transport systems.

This comprehensive review examines nine peptides with documented oral efficacy: BPC-157 (body protection compound), oral semaglutide (Rybelsus®), larazotide acetate, KPV tripeptide, dihexa, thymosin beta-4, collagen peptides, cyclosporine A, and the intranasal/oral peptides semax and selank.

For each peptide, we provide detailed molecular mechanisms of action, pharmacokinetic profiles, clinical trial evidence, and therapeutic applications. This review synthesizes evidence from peer-reviewed literature, clinical trials registered with ClinicalTrials.gov, and regulatory submissions to provide clinicians and researchers with an authoritative reference on oral peptide therapeutics.

Regulatory Update 4/28/2026

PEPTIDE THERAPEUTICS

FDA Regulatory Update & Proposed Timeline | April 2026

Yoon Hang Kim, MD, MPH | www.directintegrativecare.com

KEY DISTINCTION: Removal from Category 2 does NOT equal Category 1 approval. Peptides removed from Category 2 currently occupy regulatory limbo as unapproved new drugs. Full legal compounding access requires PCAC review, a favorable recommendation, and final FDA rulemaking. Until that formal publication occurs, prescribing or dispensing these compounds carries federal enforcement risk. (Source: Holt Law, April 2026; FDA.gov Docket FDA-2025-N-6895)

Regulatory Timeline

Sept 2023	FDA adds 19 peptides to Category 2 (significant safety concerns), halting all 503A compounding overnight. Affected: BPC-157, TB-500, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu (injectable), Thymosin Alpha-1, Semax, Selank, Epitalon, KPV, MOTS-C, Melanotan II, LL-37, PEG-MGF, GHRP-2, GHRP-6, Ibutamoren, Kisspeptin-10.
Sept 2024	FDA removes 5 peptides from Category 2 (nominations withdrawn): AOD-9604, CJC-1295, Ipamorelin, Thymosin Alpha-1, Selank — effective Sept 27, 2024. Status: regulatory limbo — removed from Category 2 but not yet on approved compounding list. PCAC review scheduled.
Oct–Dec 2024	PCAC meetings held. Oct 29: Ipamorelin, Ibutamoren, Kisspeptin reviewed — FDA recommended NONE be included on 503A Bulks List. Dec 4: AOD-9604, CJC-1295, Thymosin Alpha-1 reviewed. Outcome: PCAC accepted FDA staff recommendations against inclusion for most peptides reviewed in this cycle. Formal rulemakings pending.
Feb 27, 2026	HHS Secretary RFK Jr. announces on Joe Rogan Experience (Episode #2461) that ~14 of 19 Category 2 peptides will return to legal compounding status. Rationale: Category 2 restrictions "created the gray market they were designed to prevent." Formal FDA action to follow.
Apr 15, 2026	HHS directs FDA to remove 12 peptides from Category 2. Effective April 22, 2026 (7 calendar days from publication). Includes: BPC-157, TB-500, KPV, MOTS-C, Semax, Epitalon, Emideltide (DSIP), GHK-Cu (injectable), Melanotan II, Cathelicidin LL-37, Dihexa Acetate, and others. Each will proceed to PCAC review.
Apr 16, 2026	FDA publishes Federal Register notice (Docket FDA-2025-N-6895) formally scheduling PCAC meetings. Public comments accepted through July 22, 2026; comments by July 9 presented to committee.
Jul 23–24, 2026	PCAC Advisory Meeting — BATCH 1 (7 peptides): July 23: BPC-157 (ulcerative colitis indication), KPV (wound healing), MOTS-C, TB-500. \| July 24: Emideltide (DSIP), Epitalon, Semax.
Late 2026	FDA final determination for Batch 1 peptides expected. If PCAC recommends inclusion, FDA must publish final rule before compounding pharmacies can legally produce. Earliest estimated legal compounding access for BPC-157, TB-500, Semax, Epitalon: Late 2026–Early 2027.
By Feb 2027	PCAC Advisory Meeting — BATCH 2 (5+ peptides): GHK-Cu (injectable), Melanotan II, CJC-1295 (status disputed), Cathelicidin LL-37, and others. Final rulemakings for Batch 2 compounds: 2027 at earliest.

Projected Peptide Status (Based on April 2026 Announcements)

Expected to return to Category 1 (~14 peptides)	Expected to remain restricted (~5 peptides)
✓ BPC-157 PCAC Jul 23, 2026	✗ Melanotan II cardiovascular / melanoma risk
✓ TB-500 PCAC Jul 23, 2026	✗ GHRP-2 / GHRP-6 cortisol & prolactin effects
✓ Thymosin Alpha-1 PCAC Dec 2024 reviewed	✗ CJC-1295 cardiac AE signal; status disputed
✓ Ipamorelin PCAC Oct 2024 reviewed	✗ LL-37 (Cathelicidin) insufficient human safety data
✓ AOD-9604 PCAC Dec 2024 reviewed	✗ PEG-MGF minimal clinical evidence
✓ GHK-Cu (injectable) PCAC by Feb 2027
✓ Selank Removed Sept 2024
✓ Semax PCAC Jul 24, 2026
✓ KPV PCAC Jul 23, 2026
✓ MOTS-C PCAC Jul 23, 2026
✓ Epitalon PCAC Jul 24, 2026
✓ Emideltide (DSIP) PCAC Jul 24, 2026

Clinical Guidance for Prescribers

Do not prescribe or dispense any peptide still in Category 2 limbo. "Removed from Category 2" is not a green light — legal compounding requires final FDA rulemaking.
Monitor FDA.gov and Docket FDA-2025-N-6895 for formal publication of PCAC outcomes.
Submit written public comments before July 9, 2026 deadline to support PCAC review for specific peptides.
"Research use only" sourcing provides zero legal defense. Only use pharmaceutical-grade compounds from licensed 503A/503B pharmacies with current COAs.
WADA status is separate from FDA status. Even if a peptide receives 503A approval, it may remain prohibited in competitive sport.

Yoon Hang "John" Kim, MD, MPH | Board-Certified in Preventive Medicine | Integrative & Functional Medicine

20+ years experience | Fellowship-trained at University of Arizona under Dr. Andrew Weil | Author of 3 books & 20+ articles

www.yoonhangkim.com | www.directintegrativecare.com | Virtual: IA | IL | MO | FL | GA | TX

Introduction to Oral Peptide Delivery
BPC-157 (Body Protection Compound-157)
Oral Semaglutide (Rybelsus®)
Larazotide Acetate
KPV Tripeptide
Dihexa
Thymosin Beta-4
Collagen Peptides
Cyclosporine A
Semax and Selank
Comparative Analysis and Future Directions
References

1. Introduction to Oral Peptide Delivery

1.1 Challenges in Oral Peptide Bioavailability

Oral delivery of peptide and protein therapeutics faces immense challenges due to the hostile gastrointestinal environment. Major barriers include:

Enzymatic degradation by pepsin, trypsin, chymotrypsin, and brush-border peptidases
Poor permeation across the intestinal epithelium due to high molecular weight and hydrophilicity
Variable pH conditions from stomach (pH 1-3) to intestine (pH 6-7.4)
Intestinal mucus layer, which impedes access to the epithelium (Aguirre et al., 2016; Hubálek et al., 2013)

Despite these challenges, over 240 peptide and protein drugs have been FDA-approved, though most require parenteral administration. Only a few peptides have achieved clinically meaningful oral bioavailability through unique structural properties or innovative formulations (Yang et al., 2022).

1.2 Strategies for Enhancing Oral Peptide Absorption

Several pharmaceutical approaches overcome oral peptide barriers:

Absorption enhancers: Compounds that transiently open tight junctions or increase membrane fluidity (e.g., SNAC in oral semaglutide)
Chemical modification: N-methylation, cyclization, incorporation of non-natural amino acids
Encapsulation systems: Liposomes, nanoparticles, hydrogels
Targeted delivery: Intestinal transporters such as PepT1 for di/tripeptide uptake
Intrinsic stability: Some peptides naturally resist gastric degradation

2. BPC-157 (Body Protection Compound-157)

2.1 Overview and Structure

BPC-157 is a pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; 1,419 Da), derived from human gastric juice protein BPC, naturally secreted in the stomach (Sikiric et al., 2018).

2.2 Oral Bioavailability and Stability

BPC-157 remains intact for over 24 hours in human gastric juice, allowing oral administration without specialized carriers. Typical doses in preclinical studies: 200–500 μg/kg (Gwyer et al., 2019).

Half-life in plasma: <30 minutes
Therapeutic effects persist for weeks to months, likely via gene expression changes (Sikiric et al., 2020)

2.3 Molecular Mechanisms of Action

2.3.1 VEGFR2-PI3K-Akt-eNOS Pathway

Promotes angiogenesis, vasodilation, and tissue repair via VEGFR2 activation and NO production (Hsieh et al., 2017).

2.3.2 Src-Caveolin-1-eNOS Pathway (VEGF-Independent)

Activates eNOS independently of VEGF, explaining efficacy where VEGF signaling is impaired (Hsieh et al., 2020).

2.3.3 ERK1/2 Signaling and Cellular Migration

Stimulates endothelial and fibroblast proliferation/migration through ERK1/2 and FAK-paxillin pathways (Huang et al., 2019).

2.3.4 Anti-Inflammatory Effects

Reduces COX-2, myeloperoxidase, IL-6, TNF-α, and upregulates HO-1 and heat shock proteins (Sikiric et al., 2018).

2.3.5 Neurotransmitter Modulation

Modulates dopaminergic and serotonergic systems, restoring glutamatergic signaling (Sikiric et al., 2021).

2.4 Clinical Evidence

Phase I Safety Trial: Favorable safety in healthy volunteers (NCT02637284)
Musculoskeletal Applications: 58% sustained pain relief in knee pain case series (Vasireddi et al., 2025)
Interstitial Cystitis: 12 patients showed symptom improvement (Lee & Burgess, 2024)
Intravenous Safety: Pilot study showed no adverse effects (Lee & Burgess, 2025)

3. Oral Semaglutide (Rybelsus®)

3.1 Overview

First FDA-approved oral GLP-1 receptor agonist for type 2 diabetes (approved 2019). Combines semaglutide with SNAC, a small fatty acid derivative that facilitates absorption (Lewis & Richard, 2021).

3.2 SNAC Mechanism of Action

Local pH Buffering: Protects semaglutide from gastric degradation
Peptide Monomerization: Prevents oligomer formation, enhancing absorption
Membrane Fluidization: Transiently increases epithelial permeability (Buckley et al., 2018; Aroda et al., 2022)

3.3 Pharmacokinetics

Absolute bioavailability: 0.8–1.4%
Absorption occurs primarily in the stomach
Fasting duration affects bioavailability (Granhall et al., 2019)

3.4 PIONEER Clinical Trial Program

Total enrollment: 9,543; 5,707 randomized to oral semaglutide

4. Larazotide Acetate

4.1 Overview

Synthetic octapeptide for celiac disease adjunct therapy; acts locally in the intestine with minimal systemic absorption (Leffler et al., 2015).

4.2 Mechanism of Action

Zonulin Antagonism: Prevents gluten-induced tight junction disassembly (Gopalakrishnan et al., 2012)
Tight Junction Protection: Maintains intestinal barrier integrity; enteric-coated for targeted delivery (Paterson et al., 2007)

4.3 Clinical Trial Evidence

Phase 2b Trial: 26% reduction in symptomatic days; safe and well-tolerated (Leffler et al., 2015)
Phase 3 CeDLara Trial: Discontinued due to insufficient effect size (ClinicalTrials.gov, 2022)

5. KPV Tripeptide

5.1 Overview

Tripeptide Lys-Pro-Val, derived from α-MSH; anti-inflammatory via PepT1 transporter (Dalmasso et al., 2008).

5.2 Mechanism of Action

PepT1-Mediated Transport: High-affinity uptake at inflamed intestinal sites
NF-κB Inhibition: Prevents pro-inflammatory gene transcription
MAP Kinase Inhibition: Blocks ERK1/2, JNK, p38 phosphorylation

5.3 Preclinical Evidence

Reduces colitis severity in mouse models; nanoparticle delivery enhances colonic targeting (Xiao et al., 2017)

6. Dihexa

6.1 Overview

Synthetic hexapeptide, promotes cognitive function and neurogenesis (Benoist et al., 2014).

6.2 Mechanism of Action

HGF Mimetic: Binds and activates c-Met receptor
Synaptogenesis: Promotes dendritic spine formation and neurite outgrowth
Neurogenesis: Potent effects compared to BDNF

6.3 Preclinical Evidence

Rat studies show cognitive improvement; human trials limited

7. Thymosin Beta-4

7.1 Overview

43-amino-acid peptide involved in tissue repair, angiogenesis, and anti-inflammatory responses (Goldstein & Kleinman, 2012).

7.2 Mechanism of Action

Actin binding and cytoskeletal regulation
Cell migration, angiogenesis
Anti-inflammatory and anti-apoptotic effects

7.3 Clinical Evidence

Accelerated healing in pressure ulcers, venous stasis ulcers, and epidermolysis bullosa

8. Collagen Peptides

8.1 Overview

Hydrolyzed collagen fragments (2–5 kDa) with improved oral bioavailability (Virgilio et al., 2024).

8.2 Absorption and Bioavailability

Absorbed as intact di- and tripeptides (~63.4%)
Key metabolites: Pro-Hyp, Hyp-Gly, Gly-Pro-Hyp
Hydroxyproline confers stability

8.3 Clinical Evidence

Daily doses of 2.5–15 g improve skin, joint health, and wound healing (Virgilio et al., 2024; Choi et al., 2014)

9. Cyclosporine A

9.1 Overview

11-amino-acid cyclic peptide immunosuppressant; oral bioavailability 20–70% despite >500 Da molecular weight (Wang & Craik, 2016).

9.2 Structural Features

N-Methylation, non-canonical amino acids
Chameleonic conformational behavior
Cyclic backbone protects against degradation

10. Semax and Selank

10.1 Semax

Synthetic heptapeptide ACTH(4-10) analogue
Upregulates BDNF and NGF, enhances dopaminergic/serotonergic systems
Intranasal administration more potent for cognitive effects

10.2 Selank

Synthetic heptapeptide tuftsin analogue
Modulates GABAergic neurotransmission, anxiolytic and nootropic
Increases BDNF mRNA and protein (Vasileva et al., 2020)

11. Comparative Analysis and Future Directions

11.1 Mechanisms Enabling Oral Bioavailability

Intrinsic stability: BPC-157
Absorption enhancers: Oral semaglutide
Local action: Larazotide
Active transport: KPV
Hydroxyproline protection: Collagen peptides
Structural modification: Cyclosporine A

11.2 Regulatory Considerations

Approved: Oral semaglutide (Rybelsus®), cyclosporine A
Phase 2/3: Larazotide, Tβ4
Research use: BPC-157, KPV, dihexa, semax/selank

11.3 Future Directions

Novel absorption enhancers beyond SNAC
Nanoparticle/hydrogel delivery systems
Rational peptide design for oral bioavailability
Microbiome-based delivery strategies

https://www.youtube.com/watch?v=qNxc1mc9yA8

Meet Yoon Hang Kim MD Integrative & Functional Medicine Expert

12. References

(APA format preserved, hyperlinks retained)

Aguirre, T. A. S., Teijeiro-Osorio, D., Rosa, M., Coulter, I. S., Alonso, M. J., & Brayden, D. J. (2016). Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials. Advanced Drug Delivery Reviews, 106, 223-241. https://doi.org/10.1016/j.addr.2016.02.004

Aroda, V. R., Blonde, L., & Engström, P. G. (2022). A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Reviews in Endocrine and Metabolic Disorders, 23(5), 979-994. https://doi.org/10.1007/s11154-022-09735-8

Benoist, C. C., Kawas, L. H., Zhu, M., Bhagat, S., Bhakta, D., Lin, G., ... Wright, J. W. (2014). The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. Journal of Pharmacology and Experimental Therapeutics, 351(2), 390-402. https://doi.org/10.1124/jpet.114.218735

Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahlgren, J., ... Falk, M. (2018). Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine, 10(467), eaar7047. https://doi.org/10.1126/scitranslmed.aar7047

Choi, S. Y., Ko, E. J., Lee, Y. H., Kim, B. G., Shin, H. J., Seo, D. B., ... Kim, M. N. (2014). Effects of collagen tripeptide supplement on skin properties: A prospective, randomized, controlled study. Journal of Cosmetic and Laser Therapy, 16(3), 132-137. https://doi.org/10.3109/14764172.2013.854119

Dalmasso, G., Charrier-Hisamuddin, L., Nguyen, H. T. T., Yan, Y., Sitaraman, S., & Bhatt, D. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 134(1), 166-178. https://doi.org/10.1053/j.gastro.2007.10.026

Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., ... Myasoedov, N. F. (2006). Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry, 97(Suppl 1), 82-86. https://doi.org/10.1111/j.1471-4159.2006.03766.x

Goldstein, A. L., & Kleinman, H. K. (2012). Thymosin β4: A multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 12(1), 37-51. https://doi.org/10.1517/14712598.2012.637506

Gopalakrishnan, S., Durai, M., Kitchens, K., Tamiz, A. P., Somerville, R., Ginski, M., ... Bhati, A. P. (2012). Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides, 35(1), 86-94. https://doi.org/10.1016/j.peptides.2012.02.015

Granhall, C., Donsmark, M., Blicher, T. M., Golor, G., Søndergaard, F. L., Thomsen, M., & Bækdal, T. A. (2019). Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes. Clinical Pharmacokinetics, 58(6), 781-791. https://doi.org/10.1007/s40262-018-0728-4

Gwyer, D., Wragg, N. M., & Wilson, S. L. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(2), 153-159. https://doi.org/10.1007/s00441-019-03016-8

Hsieh, M. J., Lee, C. H., Chueh, H. Y., Chang, G. J., Huang, H. Y., Lin, Y., & Peng, Y. J. (2020). Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Scientific Reports, 10, 17078. https://doi.org/10.1038/s41598-020-74022-y

Hsieh, M. J., Liu, H. T., Wang, C. N., Huang, H. Y., Lin, Y., Ko, Y. S., ... & Peng, Y. J. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine, 95(3), 323-333. https://doi.org/10.1007/s00109-016-1488-y

Hubálek, F., Refsgaard, H. H. F., Gram-Nielsen, S., Madsen, P., Nishimura, E., Münzel, M., ... & Hjortkjær, R. K. (2013). Approaches for enhancing oral bioavailability of peptides and proteins. International Journal of Pharmaceutics, 447(1-2), 75-93. https://doi.org/10.1016/j.ijpharm.2013.02.030

Huang, T., Zhang, K., Sun, L., Xue, X., Zhang, C., Shu, Z., ... & Yang, W. (2019). Body protective compound-157 enhances tendon-bone healing in a rotator cuff tear model. Connective Tissue Research, 60(3), 241-249. https://doi.org/10.1080/03008207.2018.1505530

Lee, E., & Burgess, K. (2024). Treatment of interstitial cystitis with BPC-157: A case series. Alternative Therapies in Health and Medicine, 30(3), 48-52.

Lee, E., & Burgess, K. (2025). Safety of intravenous infusion of BPC157 in humans: A pilot study. Alternative Therapies in Health and Medicine, 31, 20-24.

Leffler, D. A., Kelly, C. P., Green, P. H. R., Fedorak, R. N., DiMarino, A., Perrow, W., ... Murray, J. A. (2015). Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: A randomized controlled trial. Gastroenterology, 148(7), 1311-1319.e6. https://doi.org/10.1053/j.gastro.2015.02.008

Lewis, A. L., & Richard, J. (2021). Development and approval of rybelsus (oral semaglutide): Ushering in a new era in peptide delivery. Therapeutic Delivery, 12(5), 1-4. https://doi.org/10.4155/tde-2021-0048

Oesser, S., Adam, M., Babel, W., & Seifert, J. (1999). Oral administration of 14C labelled gelatin hydrolysate leads to an accumulation of radioactivity in cartilage of mice (C57/BL). The Journal of Nutrition, 129(10), 1891-1895. https://doi.org/10.1093/jn/129.10.1891

Paterson, B. M., Lammers, K. M., Arrieta, M. C., Fasano, A., & Meddings, J. B. (2007). The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: A proof of concept study. Alimentary Pharmacology & Therapeutics, 26(5), 757-766. https://doi.org/10.1111/j.1365-2036.2007.03413.x

Sikiric, P., Seiwerth, S., Rucman, R., Turkovic, B., Rokotov, D. S., Brcic, L., ... Stupnisek, M. (2018). Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications. Current Neuropharmacology, 16(1), 19-29. https://doi.org/10.2174/1570159X15666170703101926

Sikiric, P., Hahm, K. B., Blagaic, A. B., Tvrdeic, A., Pavlov, K. H., Petrovic, A., ... Seiwerth, S. (2020). Stable gastric pentadecapeptide BPC 157 and wound healing. Frontiers in Pharmacology, 11, 1050. https://doi.org/10.3389/fphar.2020.01050

Sikiric, P., Rucman, R., Turkovic, B., Seiwerth, S., Hahm, K. B., Blagaic, A. B., ... & Balenovic, I. (2021). Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157: Vascular recruitment and gastrointestinal tract healing. Current Pharmaceutical Design, 27(16), 1942-1953. https://doi.org/10.2174/1381612826666201014124146

Vasileva, E. V., Kondrakhin, E. A., Abdullina, A. A., Kudrin, V. S., Narkevich, V. B., & Kovalev, G. I. (2020). Predominance of nootropic or anxiolytic effects of selank, semax, and noopept peptides depending on the route of administration to BALB/c and C57BL/6 mice. Neurochemical Journal, 14, 268-278. https://doi.org/10.1134/S1819712420030113

Vasireddi, N., Hahamyan, H., Salata, M. J., Karns, M. R., & Voos, J. E. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: A systematic review. Orthopaedic Journal of Sports Medicine, 13(1). https://doi.org/10.1177/23259671251233916

Veljaca, M., Lesch, C. A., Pllana, R., Sanchez, B., Chan, K., & Guglietta, A. (1995). BPC-15 reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. Journal of Pharmacology and Experimental Therapeutics, 272(1), 417-422.

Virgilio, N., Schuch, B., Verburg, S., Post, J. A., Meijer, K., Breeuwsma, S., ... de Groot, A. (2024). Absorption of bioactive peptides following collagen hydrolysate intake: A randomized, double-blind crossover study in healthy individuals. Frontiers in Nutrition, 11, 1416643. https://doi.org/10.3389/fnut.2024.1416643

Wang, C. K., & Craik, D. J. (2016). Cyclic peptide oral bioavailability: Lessons from the past. Biopolymers (Peptide Science), 106(6), 901-909. https://doi.org/10.1002/bip.22878

Xiao, B., Xu, Z., Viennois, E., Zhang, Y., Zhang, Z., Zhang, M., ... Merlin, D. (2017). Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Molecular Therapy, 25(7), 1628-1640. https://doi.org/10.1016/j.ymthe.2016.11.020

Yang, Z., Zhang, L., Wei, J., Li, S., Liu, Y., Ding, L., ... Li, Q. (2022). Oral delivery of protein and peptide drugs: From non-specific formulation approaches to intestinal cell targeting strategies. Theranostics, 12(3), 1419-1439. https://doi.org/10.7150/thno.67284Disclaimer

This review is intended for educational and research purposes only. Regulatory status varies among peptides. Oral semaglutide (Rybelsus®) and cyclosporine A are FDA-approved; others are investigational, research chemicals, or supplements. Consult current prescribing information before use. This content is not medical advice.